Back to all studies
CompletedNCT01259492

Methylphenidate HCl Extended Release for ADHD

This study is completed in the United States, in Belgium, in Colombia, .... It is testing Methylphenidate HCl Extended Release for ADHD.

ADHD, Attention Deficit/Hyperactivity DisorderDrugFrom 18 Years to 60 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether Methylphenidate Hydrochloride Extended Release may be useful for children experiencing ADHD.

What would participation involve?

Participants may receive Methylphenidate Hydrochloride Extended Release, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Belgium, in Colombia, and in Denmark.

Who is it mainly for?

This study appears to be mainly for children with ADHD. Because it involves minors, a parent or guardian may need to be involved.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateNovember 2010
Recruitment status
Completed
Enrollment listed in the registry
725
Sponsor
Novartis Pharmaceuticals
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Belgium, Colombia, ...
Age range
From 18 Years to 60 Years
Official registry ID
NCT01259492
Official title
A 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate HCl Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Belgium · 6 sites
  • Novartis Investigative Site
    Bruges, Belgium
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Heusden-Zolder, Belgium
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Kortenberg, Belgium
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Uccle, Belgium
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Kessel-Lo
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Mechelen
    Site status: Not listed — confirm with the team
Colombia · 3 sites
  • Novartis Investigative Site
    Santa Fe de Antioquia, Antioquia
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Antioquia
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Bogotá
    Site status: Not listed — confirm with the team
Denmark · 1 site
  • Novartis Investigative Site
    Århus C
    Site status: Not listed — confirm with the team
Germany · 28 sites
  • Novartis Investigative Site
    Ahrensburg, Germany
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Bamberg, Germany
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Berlin, Germany
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Essen, Germany
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Hamburg, Germany
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Kiel, Germany
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Ludwigsburg, Germany
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Mainz, Germany
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    München, Germany
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Naumburg, Germany
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Nuremberg, Germany
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Wolfsburg, Germany
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Berlin
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Dresden
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Ellwangen
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Freiburg im Breisgau
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Freiburg im Breisgau
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Hagen
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Hanover
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Homburg
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Landau
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Leipzig
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Limburg
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Mannheim
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Siegen
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Ulm
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Westerstede/Oldenburg
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Würzburg
    Site status: Not listed — confirm with the team
Norway · 2 sites
  • Novartis Investigative Site
    Porsgrunn, Norway
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Skien
    Site status: Not listed — confirm with the team
Singapore · 1 site
  • Novartis Investigative Site
    Singapore
    Site status: Not listed — confirm with the team
South Africa · 3 sites
  • Novartis Investigative Site
    Benoni
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Melrose Arch
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Pretoria
    Site status: Not listed — confirm with the team
Sweden · 3 sites
  • Novartis Investigative Site
    Luleå
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Malmö
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Stockholm
    Site status: Not listed — confirm with the team
United States · 21 sites
  • Novartis Investigative Site
    Little Rock, Arkansas
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Beverly Hills, California
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Spring Valley, California
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Bradenton, Florida
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Miami, Florida
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Orlando, Florida
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    West Plam Beach, Florida
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Libertyville, Illinois
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Owensboro, Kentucky
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Troy, Michigan
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Las Vegas, Nevada
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Las Vegas, Nevada
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Willingboro, New Jersey
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Fargo, North Dakota
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Columbus, Ohio
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Oklahoma City, Oklahoma
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Philadelphia, Pennsylvania
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Houston, Texas
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Houston, Texas
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Bellevue, Washington
    Site status: Not listed — confirm with the team
  • Novartis Investigative Site
    Seattle, Washington
    Site status: Not listed — confirm with the team

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT01259492. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Placebo, Ritalin LA 20 mg, Ritalin LA 30 mg. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with adhd; age range: From 18 Years to 60 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Novartis Pharmaceuticals, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me